Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
24.76
+0.26 (1.06%)
Sep 16, 2025, 12:15 PM EDT - Market open
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $730.00K in the quarter ending June 30, 2025, a decrease of -70.78%. This brings the company's revenue in the last twelve months to $5.79M, down -30.27% year-over-year. In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth.
Revenue (ttm)
$5.79M
Revenue Growth
-30.27%
P/S Ratio
280.83
Revenue / Employee
$31,129
Employees
186
Market Cap
1.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CLDX News
- 6 days ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 25 days ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 27 days ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga
- 27 days ago - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 5 weeks ago - Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewsWire
- 3 months ago - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - GlobeNewsWire